Mongolian medicine characteristic enema for treating ulcerative colitis

Abstract

The invention discloses a Mongolian medicine characteristic enema for treating ulcerative colitis, and relates to the technical field of biological medicine. Raw materials of the enema comprise a Mongolian medicine composition. The Mongolian medicine composition is prepared from the following components in parts by weight: 25 to 35 parts of pomegranate seeds, 15 to 25 parts of cortex cinnamomi, 15 to 25 parts of gypsum rubrum, 15 to 25 parts of fructus amomi rotundus, 15 to 25 parts of fructus forsythiae, 15 to 25 parts of rhizoma curcumae longae, 15 to 25 parts of fructus chebulae, 15 to 25 parts of rhizoma zingiberis, 15 to 25 parts of puffball, 15 to 25 parts of caulis clematidis armandii, 5 to 15 parts of radix glycyrrhizae preparata, 5 to 15 parts of cacumen biotae, 5 to 15 parts of long pepper, 5 to 15 parts of alkali and 5 to 15 parts of rhizoma polygonati. The Mongolian medicine characteristic enema developed by the invention has remarkable technical advantages in the aspect of treating ulcerative colitis, including improvement of the local action effect of the medicine, reduction of untoward effects, definite clinical curative effect and innovative Mongolian medicine characteristics, and a safe, effective and economic treatment scheme can be provided for UC (ulcerative colitis) patients.

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and particularly to a Mongolian medicine characteristic enema for treating ulcerative colitis. Background Art

[0002] Data shows that the etiology and pathogenesis of about 1 / 4 of patients with colorectal cancer are related to chronic inflammation, namely colitis-associated colorectal cancer (UCACC), and its mortality rate is as high as 15%. At least several decades of precancerous evolution period are required before the emergence of UCACC. Therefore, effective treatment of chronic non-specific ulcerative colitis (UC) is the key to preventing and treating UCACC, which has practical significance.

[0003] There are a variety of methods for Western medicine to prevent and treat UCACC. Moreover, new drugs and new methods are constantly emerging. However, no matter which means is adopted, the long-term survival rate and quality of life of patients are still not ideal. At present, many scholars are trying to explore drugs that can prevent UCACC while treating UC, hoping that these drugs can reverse, inhibit, and prevent the occurrence and development of UCACC. Mongolian medicine has the characteristics of multi-system, multi-link, and multi-target regulation, with significant curative effects, low recurrence rate, and relatively small toxic and side effects, and has unique advantages in preventing and treating chronic diseases. In recent years, more and more experimental studies have affirmed the preventive and therapeutic effects of traditional Chinese medicine on UCACC.

[0004] UC is a disease with main clinical manifestations of abdominal pain, diarrhea, mucopurulent bloody stools, and tenesmus, and is accompanied by damage to multiple organs outside the intestine. Due to the repeated attacks and intractability of the UC condition, it seriously affects the quality of life of patients. Western medicine mostly uses aminosalicylate preparations, glucocorticoids, azathioprine analogs, and biological agents for treatment. However, there are deficiencies such as a long course of treatment, lack of specificity, poor curative effect, high adverse reactions, poor patient tolerance, and affecting the compliance of treatment.

[0005] UC belongs to the Mongolian medicine's "large intestine bogru disease". Mongolian medical ancient books record that "when the large intestine bogru disease lingers without cure, it accumulates into a mass under the action of the pathological khyi, and most of them are blood masses". Since ancient times, Mongolian medicine has followed the treatment principle of calming the khyi and regulating the three roots, and the curative effect of treating this disease with Mongolian medicine combined with external treatment is affirmed, and the drug's toxic and side effects are relatively small. Among them, intestinal route drug administration has particular characteristics and advantages.

[0006] At present, with the in-depth study of the physiological functions of the large intestine, drug administration through the anorectal route has gradually attracted the attention of researchers, and its scientific nature and good curative effect have been recognized. In terms of UC, enema local drug administration can directly deliver the drug to the affected area, with high drug absorption and utilization rate, few adverse reactions, and definite clinical curative effect, which is significantly better than oral drug treatment. Based on this, the present invention intends to develop a Mongolian medicine characteristic enema for treating ulcerative colitis to achieve effective treatment of ulcerative colitis. Summary of the Invention

[0007] The object of the present invention is to provide a Mongolian medicine enema for treating ulcerative colitis to solve the problems existing in the above-mentioned prior art. This Mongolian medicine enema has significant technical advantages in the treatment of ulcerative colitis.

[0008] To achieve the above object, the present invention provides the following solutions:

[0009] The present invention provides a Mongolian medicine composition for treating ulcerative colitis, comprising the following components in parts by weight:

[0010] 25 - 35 parts of pomegranate seeds, 15 - 25 parts of cinnamon, 15 - 25 parts of gypsum rubrum, 15 - 25 parts of cardamom, 15 - 25 parts of forsythia suspensa, 15 - 25 parts of turmeric, 15 - 25 parts of terminalia chebula, 15 - 25 parts of dried ginger, 15 - 25 parts of lasiosphaera seu calvatia, 15 - 25 parts of akebia quinata, 5 - 15 parts of roasted licorice root, 5 - 15 parts of oriental arborvitae, 5 - 15 parts of piper longum, 5 - 15 parts of alkali, and 5 - 15 parts of polygonatum sibiricum.

[0011] Preferably, the Mongolian medicine composition comprises the following components in parts by weight: 30 parts of pomegranate seeds, 20 parts of cinnamon, 20 parts of gypsum rubrum, 20 parts of cardamom, 20 parts of forsythia suspensa, 20 parts of turmeric, 20 parts of terminalia chebula, 20 parts of dried ginger, 20 parts of lasiosphaera seu calvatia, 20 parts of akebia quinata, 10 parts of roasted licorice root, 10 parts of oriental arborvitae, 10 parts of piper longum, 10 parts of alkali, and 10 parts of polygonatum sibiricum.

[0012] The present invention also provides the use of the above-mentioned Mongolian medicine composition in the preparation of a drug for treating ulcerative colitis.

[0013] Further, the drug is a powder or an enema.

[0014] The present invention also provides a drug for treating ulcerative colitis, the raw material of which comprises the above-mentioned Mongolian medicine composition.

[0015] Further, the drug further comprises a pharmaceutically acceptable excipient.

[0016] Further, the drug is a powder.

[0017] Further, the drug is an enema.

[0018] The present invention also provides a preparation method of the above-mentioned powder, which comprises the step of uniformly mixing the medicinal material powders of the components in the above-mentioned Mongolian medicine composition in a formulated amount to obtain the powder.

[0019] The present invention also provides a preparation method of the above-mentioned enema, which comprises the following steps;

[0020] Uniformly mixing the medicinal material powders of the components in the above-mentioned Mongolian medicine composition in a formulated amount to obtain a mixture;

[0021] Add the said mixture to distilled water, boil it, separate and remove the insoluble substances after cooling to obtain a clear liquid, which is the said enema.

[0022] Pomegranate seeds are sour, sweet in taste and neutral in nature; they have the effects of stopping diarrhea, astringing to arrest bleeding and calming Heyi, and are used for chronic diarrhea, indigestion, bloody stools and other symptoms.

[0023] Cinnamon is pungent, sweet in taste and warm in nature; it has the effects of dispelling cold and relieving pain, promoting blood circulation, and is used for palpitation, chest distress and shortness of breath and other symptoms.

[0024] Gypsum rubrum is salty in taste and warm in nature; it has the effects of detoxifying and promoting digestion, and is used for indigestion, epigastric distending pain and other symptoms.

[0025] Cardamom is pungent in taste and warm in nature; it has the effects of warming the kidney and promoting diuresis, and is used for weakness, qi stagnation in the spleen and stomach, diarrhea and other symptoms.

[0026] Forsythia suspensa is bitter in taste and slightly cold in nature; it has the effects of clearing heat and detoxifying, detumescence and dispelling Xila, and is used for carbuncles, boils and other symptoms.

[0027] Turmeric is pungent, bitter in taste and warm in nature; it has the effects of promoting qi and blood circulation, dredging meridians and relieving pain, and is used for stabbing pain in the chest and hypochondrium, amenorrhea, stasis syndrome, rheumatic pain in the shoulders and arms and other symptoms.

[0028] Terminalia chebula is bitter, sour, astringent in taste and neutral in nature; it has the effects of detoxifying and regulating the body constitution, and is used for imbalance of the three roots, bloody stools and other symptoms.

[0029] Dried ginger is pungent in taste and hot in nature; it has the effects of dispelling cold and promoting digestion, and is used for epigastric and abdominal cold pain, vomiting and diarrhea and other symptoms.

[0030] Lasiosphaera seu Calvatia is pungent in taste and neutral in nature; it has the effects of clearing the lung and relieving sore throat, detoxifying and stopping bleeding, and is used for sore throat, hoarseness, hematemesis, epistaxis and other symptoms.

[0031] Clematis armandii Franch. is bitter in taste and cold in nature; it has the effects of clearing heart fire, promoting diuresis and dredging meridians, and is used for edema, vexation with scanty and red urine, sores and ulcers on the tongue, amenorrhea and scanty lactation and other symptoms.

[0032] Honey-fried Licorice Root is sweet in taste and neutral in nature; it has the effects of invigorating the spleen and stomach, replenishing qi and relieving cough, and is used for weakness of the spleen and stomach, cough and asthma and other symptoms.

[0033] Biota orientalis (L.) Endl. is bitter, astringent in taste and cold in nature; it has the effects of cooling blood to stop bleeding, resolving phlegm and relieving cough, and is used for hemoptysis, epistaxis, hematuria and other symptoms.

[0034] Piper longum L. is pungent in taste and hot in nature; it has the effects of dispelling cold and relieving pain, and is used for epigastric and abdominal cold pain, vomiting and diarrhea and other symptoms.

[0035] Polygonatum sibiricum Redoute is sweet in taste and neutral in nature; it has the effects of strengthening the spleen, moistening the lung and tonifying the kidney, and is used for weakness of the spleen and stomach, fatigue, poor appetite, deficiency of essence and blood and other symptoms.

[0036] The present invention discloses the following technical effects:

[0037] The present invention is based on the theory of Mongolian medicine. By statistically analyzing the Mongolian medicines used for enema treatment of large intestine Baoru disease in ancient and modern times, combined with the pathogenesis of ulcerative colitis, the appropriate drugs are selected and scientifically matched, thereby developing a Mongolian medicine composition for treating ulcerative colitis with Mongolian medicine characteristics. Furthermore, based on the Mongolian medicine composition, a Mongolian medicine enema specially used for treating ulcerative colitis is developed. The invention fully reflects the unique value and advantages of Mongolian medicine theory in modern disease treatment, and provides new ideas and methods for the treatment of ulcerative colitis.

[0038] The Mongolian medicine enema developed by the present invention combines traditional Mongolian medicine theory with modern pharmaceutical technology, and is designed based on the pathological characteristics of UC. Experimental data show that the enema can significantly reduce the colon inflammation score of model rats and improve colon tissue pathological changes. In addition, in clinical trials, patients showed a higher cure rate and a lower recurrence rate after using it, which fully proves its definite efficacy.

[0039] The Mongolian medicine enema developed by the present invention has significant technical advantages in the treatment of ulcerative colitis, including improving the local effect of the drug, reducing adverse reactions, clear clinical efficacy and innovative Mongolian medicine characteristics, and can provide a safe, effective and economical treatment plan for UC patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0041] Figure 1 The statistical chart of the gross morphological scores of the colon mucosa of rats in each group; ☆ represents the comparison with the SASP group, P>0.05; ◇ represents the comparison with the traditional agent group, P<0.05; ★ represents the comparison with the normal group, P<0.05; ※ represents the comparison with the model control group, P<0.05;

[0042] Figure 2 The results of histopathological examination of colon mucosa of rats in each group are shown in the figure; ☆ represents the comparison with SASP group, P>0.05; ◇ represents the comparison with traditional agent group, P<0.05; ★ represents the comparison with normal group, P<0.05; ※ represents the comparison with model control group, P<0.05;

[0043] Figure 3Colon tissue staining diagrams of each group of rats; among them, A - G are the normal group, model control group, low - dose You group, medium - dose You group, high - dose You group, traditional group, and mesalazine group, respectively. Detailed implementation manners

[0044] Now, various exemplary implementation manners of the present invention will be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, characteristics, and implementation schemes of the present invention.

[0045] It should be understood that the terms described in the present invention are only for describing specific implementation manners and are not used to limit the present invention. Additionally, for the numerical ranges in the present invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any intermediate value within any stated value or stated range, as well as each smaller range between any other stated value or intermediate value within the stated range, is also included in the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0046] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention pertains. Although the present invention only describes preferred methods and materials, any methods and materials similar or equivalent to those described herein can also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials related to the documents. In case of conflict with any incorporated document, the content of this specification shall prevail.

[0047] Without departing from the scope or spirit of the present invention, various improvements and changes can be made to the specific implementation manners of the present invention specification, which are obvious to those skilled in the art. Other implementation manners obtained from the present invention specification are also obvious to those skilled in the art. The present invention specification and examples are only exemplary.

[0048] Regarding the terms "comprising", "including", "having", "containing", etc. used herein, they are all open - ended terms, meaning including but not limited to.

[0049] Example 1

[0050] Raw material formula: 30 g of pomegranate seeds, 20 g of cinnamon, 20 g of cold - water stone, 20 g of cardamom, 20 g of forsythia, 20 g of turmeric, 20 g of terminalia chebula, 20 g of dried ginger, 20 g of puffball, 20 g of akebia stem, 10 g of roasted licorice, 10 g of oriental arborvitae twig, 10 g of piper longum, 10 g of edible alkali, and 10 g of polygonatum sibiricum.

[0051] Preparation method of a Mongolian medicine - characteristic enema for treating ulcerative colitis:

[0052] (1) Crush the Mongolian medicine raw materials in the above raw material formula, and pass through a 100-mesh sieve to obtain the medicinal powder of each Mongolian medicine raw material.

[0053] (2) Mix the medicinal powders of each raw material evenly according to the above raw material formula to obtain a mixture.

[0054] (3) Take 5 g of the mixture, add 100 mL of distilled water, boil and then naturally cool to room temperature. After separating the insoluble substances, obtain the clear liquid, which is the Mongolian medicine characteristic enema for treating ulcerative colitis.

[0055] Example 2

[0056] Raw material formula: 35 g of pomegranate seeds, 15 g of cinnamon, 25 g of gypsum rubrum, 25 g of cardamom, 15 g of forsythia, 15 g of turmeric, 25 g of terminalia chebula, 25 g of dried ginger, 25 g of lasiosphaera seu calvatia, 15 g of akebia quinata, 15 g of roasted licorice root, 5 g of oriental arborvitae, 5 g of piper longum, 5 g of alkali, and 15 g of polygonatum sibiricum.

[0057] Preparation method of the Mongolian medicine characteristic enema for treating ulcerative colitis:

[0058] (1) Crush the Mongolian medicine raw materials in the above raw material formula, and pass through a 100-mesh sieve to obtain the medicinal powder of each Mongolian medicine raw material.

[0059] (2) Mix the medicinal powders of each raw material evenly according to the above raw material formula to obtain a mixture.

[0060] (3) Take 5 g of the mixture, add 100 mL of distilled water, boil and then naturally cool to room temperature. After separating the insoluble substances, obtain the clear liquid, which is the Mongolian medicine characteristic enema for treating ulcerative colitis.

[0061] Example 3

[0062] Raw material formula: 25 g of pomegranate seeds, 25 g of cinnamon, 15 g of gypsum rubrum, 15 g of cardamom, 25 g of forsythia, 25 g of turmeric, 15 g of terminalia chebula, 15 g of dried ginger, 15 g of lasiosphaera seu calvatia, 15 g of akebia quinata, 5 g of roasted licorice root, 15 g of oriental arborvitae, 15 g of piper longum, 15 g of alkali, and 5 g of polygonatum sibiricum.

[0063] Preparation method of the Mongolian medicine characteristic enema for treating ulcerative colitis:

[0064] (1) Crush the Mongolian medicine raw materials in the above raw material formula, and pass through a 100-mesh sieve to obtain the medicinal powder of each Mongolian medicine raw material.

[0065] (2) Mix the medicinal powders of each raw material evenly according to the above raw material formula to obtain a mixture.

[0066] (3) Take 5 g of the mixture, add 100 mL of distilled water, boil and then naturally cool to room temperature. After separating the insoluble substances, obtain the clear liquid, which is the Mongolian medicine characteristic enema for treating ulcerative colitis.

[0067] Effect verification example

[0068] 1. Experimental materials

[0069] Experimental animals: SPF - grade male SD rats, 6 - 8 weeks old, weighing about 180 - 220 g, purchased from Beijing Speifo Biotechnology Co., Ltd. with the license number SCXK(Beijing)2019 - 0010.

[0070] 2. Experimental methods

[0071] 2.1 Preparation of experimental drugs

[0072] Low, medium, and high - dose Mongolian medicine enema: Using the equivalent dose conversion method for human and animal drugs, the administered doses for rats were calculated. The low dose was 0.675 g / kg, the medium dose was 1.35 g / kg, and the high dose was 2.70 g / kg. According to the raw material formula and preparation method of Example 1, Mongolian medicine enemas with different doses were prepared.

[0073] Mesalazine (SASP): Using the equivalent dose conversion method for human and animal drugs, the dosage of mesalazine was calculated as 0.36 g / kg, and it was fully mixed in distilled water for standby.

[0074] Traditional Niruhaji: A traditional formula recorded in the classic Mongolian medicine "Four Parts of Sweet Dew".

[0075] 2.2 Grouping of experimental animals

[0076] The rats were placed in a laboratory at room temperature of 22°C and relative humidity of 50%, given sufficient feed and drinking water, and adaptively fed for 7 days. During this period, the body weights of the rats increased steadily, and there were no obvious differences in their daily behaviors. They were randomly divided into a normal group, a model control group, a low - dose group, a medium - dose group, a high - dose group, a mesalazine group (SASP), and a traditional group, with 12 rats in each group.

[0077] 2.3 Modeling

[0078] After the adaptive feeding, the rats in each group were fasted for 24 h. For all groups except the normal group, the TNBS / ethanol method was used for modeling. The method was as follows: A silicone tube with a diameter of 2 mm (one end fixed to a 1 - mL syringe and the other end coated with liquid paraffin) was inserted into the anus, with an insertion length of about 8 cm. A mixed reagent prepared by mixing 100 mg / kg TNBS + 0.25 mL of 50% absolute ethanol was injected into the intestinal cavity at a constant speed, and then the rats were held upside down for 3 min. The normal group was given distilled water according to their body weights and then conventionally raised.

[0079] Modeling evaluation:

[0080] After modeling, observe the general conditions of the rats such as mental state, food intake, and defecation, and give DAI scores. Furthermore, observe the general changes in the rat colon to evaluate whether the modeling is successful.

[0081] 1) General conditions: Compared with the normal group, other rats showed reduced daily food intake and water intake, fluffy hair, poor color, and reduced activity.

[0082] 2) DAI score: According to the instructions of the fecal occult blood qualitative detection kit (FOB), use a medical cotton swab to dip an appropriate amount of rat feces. Immediately showing blue-black-brown is (+), which represents a large amount of occult blood; showing blue within 30 - 60 s after adding the reagent is (±), which represents a small amount of occult blood; not showing color after 2 min is (-), which represents no occult blood. Furthermore, record the rat body weight every day.

[0083] 3) General changes in the colon: On the 3rd day after modeling, randomly select 2 rats from the normal group and the model group for sampling. Observe the inner wall of the colon macroscopically, and carefully observe whether there are ulcers, edema, adhesions or perforations and changes in the colon length. The inner wall of the colon of the rats in the model group had ulcers, edema, and the colon length was shortened, etc.

[0084] 2.4 Animal administration

[0085] Start drug enema treatment 3 days after modeling observation. Before enema, gently massage the abdomen, back and perianal area of the rats to drain the feces completely. The drug administration of each group is shown in Table 3.

[0086] Table 3 Experimental grouping

[0087] Group Drug administration Normal group Enema with distilled water, once a day for 14 consecutive days. Model control group Model establishment + enema with distilled water, once a day for 14 consecutive days. High-dose group Model establishment + high-dose Mongolian medicine characteristic enema; once a day for 14 consecutive days of treatment. Medium-dose group Model establishment + medium-dose Mongolian medicine characteristic enema; once a day for 14 consecutive days of treatment. Low-dose group Model establishment + low-dose Mongolian medicine characteristic enema; once a day for 14 consecutive days of treatment. Traditional group Model establishment + traditional Niruhaji; once a day for 14 consecutive days of treatment. SASP group Model establishment + mesalazine; once a day for 14 consecutive days of treatment.

[0088] 2.5 Specimen collection

[0089] 14 days after drug enema treatment, the rats are fasted but allowed to drink water for 24 h, anesthetized by intraperitoneal injection of 20% urethane at a dose of 1.2 g / kg, and sacrificed by decapitation. Use surgical scissors to cut along the midline of the abdomen, take the colon tissue from the rectum to the cecum, cut it longitudinally, and wash the dirt in the intestinal cavity with normal saline. Divide it into two sections, fix one part in paraformaldehyde for HE and IHC staining. The remaining part is put into a sterile and enzyme-free cryopreservation tube and immediately transferred to an -80°C refrigerator.

[0090] 2.6 Index detection

[0091] 2.6.1 Disease activity index

[0092] Observe the rat body weight, whether the feces are formed, and whether there is visible blood in the stool or occult blood every day. The occult blood situation is detected using the FOB kit on the 3rd day after modeling, and on the 3rd, 8th, and 14th days of intervention treatment. According to the observation results, score according to the DAI scoring standard to further evaluate the activity degree of UC.

[0093] 2.6.2 Histopathological changes in rat colon

[0094] 1) Tissue fixation, dehydration, and clearing: Fix part of the colon in 10% paraformaldehyde and change the liquid once every 24 hours. Take 0.5 cm and put it into an embedding cassette, and rinse it under running water for 2 hours. Place it in 75% absolute ethanol for 1 hour, 85% absolute ethanol for 1 hour, 90% absolute ethanol for 1 hour, 95% absolute ethanol for 1 hour, and 100% absolute ethanol for 40 minutes each time for two times to dehydrate the tissue. Use xylene for 15 minutes each time for two times to clear the tissue.

[0095] 2) Wax infiltration, embedding, and sectioning: Immerse it in 60°C liquid wax in a biological tissue embedding machine for 1 hour. Vertically place the wax-infiltrated colon tube in the central position of the mold, drop the dissolved liquid wax into the mold, and place it on the freezing table for about 3 minutes after it is full. Place the wax block in a -20°C refrigerator for pre-cooling for 20 minutes, then fix the frozen wax block on the microtome, trim it, and cut sections with a thickness of 3.5 μm. Carefully transfer the cut wax sections to warm water at 42°C for spreading, pick up the tissue with an adhesive glass slide and make marks, preheat the spreading machine to 60°C and bake the slices for 40 minutes for subsequent staining.

[0096] 3) Staining and coverslipping: Use xylene for 5 minutes twice, 100%, 95%, 85%, 75% gradient ethanol for 5 minutes each, hematoxylin for 6 minutes, rinse with running water for 5 seconds, differentiation solution for 8 seconds, return to blue with warm water for 6 minutes, eosin for 8 seconds, rinse with running water for several seconds, 95% I, 95% II, 100% gradient ethanol for 2 minutes each, xylene for 5 minutes twice, cover with neutral gum, and analyze the pictures under a microscope at 200-fold magnification.

[0097] 3. Experimental results

[0098] The detection results of the gross morphology and pathological histology changes of the colon mucosa in each experimental group are shown respectively in Figure 1 - Figure 3 .

[0099] Compared with the normal group of rats, the gross morphology score of the colon mucosa in the model control group of rats was significantly increased (P < 0.05), and the pathological histology changes of the colon indicated severe mucosal damage (P < 0.05). These results show that the model of ulcerative colitis rats was successfully established.

[0100] Compared with the model control group and the traditional group, after treatment with the Mongolian medicine characteristic enema (medium and high doses) of the present invention, the gross morphology score of the colon mucosa was significantly decreased (P < 0.05), and the pathological histology changes were significantly improved.

[0101] It can be seen from the above experimental results that the Mongolian medicine characteristic enema prepared by the present invention can effectively treat ulcerative colitis.

[0102] The embodiments described above are only descriptions of the preferred embodiments of the present invention, and do not limit the scope of the present invention. Without departing from the design spirit of the present invention, various deformations and improvements made by those of ordinary skill in the art to the technical solutions of the present invention shall fall within the protection scope determined by the claims of the present invention.

Claims

1. A Mongolian medicine composition for treating ulcerative colitis, characterized in that, Comprising the following components in parts by weight: 25 - 35 parts of pomegranate seeds, 15 - 25 parts of cinnamon, 15 - 25 parts of gypsum rubrum, 15 - 25 parts of cardamom, 15 - 25 parts of forsythia suspensa, 15 - 25 parts of turmeric, 15 - 25 parts of terminalia chebula, 15 - 25 parts of dried ginger, 15 - 25 parts of lasiosphaera seu calvatia, 15 - 25 parts of akebia quinata, 5 - 15 parts of honey-fried licorice root, 5 - 15 parts of oriental arborvitae, 5 - 15 parts of piper longum, 5 - 15 parts of alkali, and 5 - 15 parts of polygonatum sibiricum.

2. The Mongolian medicine composition according to claim 1, characterized in that, Comprising the following components in parts by weight: 30 parts of pomegranate seeds, 20 parts of cinnamon, 20 parts of gypsum rubrum, 20 parts of cardamom, 20 parts of forsythia suspensa, 20 parts of turmeric, 20 parts of terminalia chebula, 20 parts of dried ginger, 20 parts of lasiosphaera seu calvatia, 20 parts of akebia quinata, 10 parts of honey-fried licorice root, 10 parts of oriental arborvitae, 10 parts of piper longum, 10 parts of alkali, and 10 parts of polygonatum sibiricum.

3. Use of a Mongolian medicine composition as claimed in claim 1 or 2 in the preparation of a medicament for treating ulcerative colitis.

4. The application according to claim 3, wherein The medicament is a powder or an enema.

5. A drug for treating ulcerative colitis, characterized in that, The raw materials include the Mongolian medicine composition as claimed in claim 1 or 2.

6. The medicament according to claim 5, characterized in that, The medicament further comprises a pharmaceutically acceptable excipient.

7. The medicament according to claim 6, characterized in that, The medicament is a powder.

8. The drug according to claim 6, characterized in that, The medicament is an enema.

9. A method for preparing a drug as described in claim 7, characterized in that, Comprising the step of uniformly mixing the powders of each medicinal material in a formula amount to obtain the medicament.

10. A method for preparing the drug according to claim 8, characterized in that, Comprising the following steps; Uniformly mixing the powders of each medicinal material in a formula amount to obtain a mixture; Adding the mixture to distilled water, boiling, cooling, and separating and removing insoluble substances to obtain a clear liquid, which is the medicament.

Images